Liebe Kinder und Jugendliche, liebe Eltern,
wir bieten in unserer Praxis ab dem Alter von 5 Jahren eine Impfung gegen das SARS-CoV-2 (Corona-) Virus an. Voraussetzung für eine Impfung ist, neben einem ärztlichen Aufklärungsgespräch, die (schriftliche) Zustimmung der (beider) Erziehungsberechtigten und ein Impfwunsch des Kindes/der/des Jugendlichen. Auf dieser Seite finden Sie die aktuellen Informationen bezüglich COVID-19 Impfungen für Kinder und Jugendliche. Bitte folgen Sie den Links:
Zum praktischen Vorgehen nehmen Sie bitte die Seite „COVID-19 Impfungen – Vorgehen“ zur Kenntnis.
Stellungnahmen zum Zulassungsverfahren der EMA für BNT Kinderimpfungen 5-12 Jahre:
Der Vollständigkeit und des gesellschaftlichen Diskurs wegen: https://u12schutz.de
How Pfizer’s Pediatric Vaccine Differs From the Adult Vaccine
Different dose size, same time interval. The kiddie dose for those 5 through 11 is 10 µg. This is one third of the dose given to adults and older children (aged ≥ 12 years). The 3-week interval between doses in the two-dose series remains unchanged and mirrors the time interval for adults.
Different buffer. The mRNA and its nanoparticle coating are the same for both versions. The buffer used to stabilize them is different. The kiddie dose buffer is tromethamine (Tris). The adult version buffer is phosphate-buffered saline (PBS). This new Tris buffer formulation makes the children’s version of the vaccine more stable, so it can be stored for longer at regular refrigerator temperatures. The vials of the children’s version can be stored unopened and undiluted in regular refrigerators for up to 10 weeks.
Different color code. To avoid confusion, the two age-based products are color-coded to make them look different. The adult version vial top and packaging are purple. The vial top and packaging for the kids‘ version are orange.
Vaccine effectiveness. Vaccine authorization was based on immunobridging and compared neutralizing antibody titers after two kiddie doses in 5- through 11-year-old children with titers from 16- through 25-year-old teens and young adults who received two adult-size doses. Vaccine efficacy for a two 10-µg dose series in 5- through 11-year-old children is 90.7%.
Vaccine side effects. Side effects include pain, redness, and swelling at the injection site, as well as fatigue, headache, and chills. Children aged 5 through 11 (who received the 10-µg dose) had less fever than the 16- through 25-year-old teens and young adults who received a 30-µg dose.
Myocarditis risk after mRNA vaccines. There were no reports of myocarditis in the more than 3000 children who received the Pfizer kiddie dose vaccine, although the study was small. Rates of postvaccination myocarditis previously reported are based on data from adults and adolescents receiving the larger adult 30-µg dose and not the smaller pediatric 10-µg dose. Myocarditis can occur after COVID-19 infection. On the basis of studies of adults, older adolescents, and teens, the risk is higher after COVID-19 infection than after mRNA vaccination. The rate of myocarditis after mRNA vaccination in children aged 5-11 years is still unknown. CDC safety surveillance for postvaccination myocarditis will continue.